Adaptimmune Therapeutics Plc (ADAP) — Capital Reinvestment Ratio
Adaptimmune Therapeutics Plc (ADAP) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow ($47.39 Million) in capital expenditures ($754.55K). See ADAP equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Adaptimmune Therapeutics Plc Capital Reinvestment Ratio (2013–2021)
This chart tracks Adaptimmune Therapeutics Plc's Capital Reinvestment Ratio across 2 annual periods. Check Adaptimmune Therapeutics Plc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc (2013–2021)
Year-by-year Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc from 2013 to 2021. For live market cap and broader valuation context, see Adaptimmune Therapeutics Plc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.82x | $10.73 Million | $8.78 Million | ▲ +2002.4% |
| 2013 | 0.04x | $37.23 Million | $1.45 Million | — |